Responses
Regular and young investigator award abstracts
Clinical trials in progress
318 Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation and/or homologous recombination repair deficiency: KEYLYNK-007
Compose a Response to This Article
Other responses
No responses have been published for this article.